Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.

Leuk Lymphoma. 2018 May;59(5):1105-1112. doi: 10.1080/10428194.2017.1365858. Epub 2017 Aug 25. PMID: 28838287.

https://pubmed.ncbi.nlm.nih.gov/28838287/